Browsing Institutt for informatikk by Author "Fleischer, Thomas"

Now showing items 1-4 of 4

  • The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer 
    Silwal-Pandit, Laxmi; Nord, Silje; Gythfeldt, Hedda; Møller, Elen Kristine; Fleischer, Thomas; Rødland, Einar Andreas; Krohn, Marit; Borgen, Elin; Garred, Øystein; Olsen, Tone; Vu, Phuong Ngoc Thi; Skjerven, Helle; Fangberget, Anne; Holmen, Marit Muri; Schlichting, Ellen; Wille, Elisabeth; Stokke, Mette Norberg; Vollan, Hans Kristian Moen; Kristensen, Vessela N.; Langerød, Anita; Lundgren, Steinar; Wist, Erik; Naume, Bjørn; Lingjærde, Ole Christian; Børresen-Dale, Anne-Lise; Engebråten, Olav (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2017)
    Purpose: Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated ...
  • PHLPP1 regulates CFTR activity and lumen expansion through AMPK 
    Lobert, Viola; Skardal, Maren; Malerød, Lene; Simensen, Julie Elisabeth; Algra, Hermine Arida; Andersen, Aram Nikolai; Fleischer, Thomas; Enserink, Hilde Abrahamsen; Liestøl, Knut; Heath, Joan K; Rusten, Tor Erik; Stenmark, Harald (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    ABSTRACT Complex organ development depends on single lumen formation and its expansion during tubulogenesis. This can be achieved by correct mitotic spindle orientation during cell division, combined with luminal ...
  • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 
    Höglander, Elen K; Nord, Silje; Wedge, David C; Lingjærde, Ole C; Silwal-Pandit, Laxmi; Gythfeldt, Hedda v; Vollan, Hans K M; Fleischer, Thomas; Krohn, Marit; Schlitchting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit M; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebraaten, Olav; Kristensen, Vessela (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) ...
  • Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations 
    Høglander, Elen; Nord, Silje; Wedge, David C; Lingjærde, Ole Christian; Silwal-Pandit, Laxmi; Gythfeldt, Hedda; Vollan, Hans Kristian Moen; Fleischer, Thomas; Krohn, Marit; Schlichting, Ellen; Borgen, Elin; Garred, Øystein; Holmen, Marit Muri; Wist, Erik; Naume, Bjørn; Van Loo, Peter; Børresen-Dale, Anne-Lise; Engebråten, Olav; Kristensen, Vessela N. (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
    Background: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...